Can hypoxia-PET map hypoxic cell density heterogeneity accurately in an animal tumor model at a clinically obtainable image contrast?

Radiotherapy and Oncology

Volumn 92, Issue 3, 2009, Pages 429-436

  Busk, Morten ^a   Horsman, Michael R ^a   Jakobsen, Steen ^b   Hansen, Kim V ^b   Bussink, Johan ^c   van der Kogel, Albert ^c   Overgaard, Jens ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

^b AUH   (Denmark)

^c RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Hypoxia; Hypoxia specificity; Image contrast; Nitroimidazoles; PET

Indexed keywords

CARBOHYDRATE DERIVATIVE; FLUORINE 18; FLUOROAZOMYCIN ARABINOSIDE; PIMONIDAZOLE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL DENSITY; CONTROLLED STUDY; DRUG DISTRIBUTION; FEMALE; HYPOXIA; IMAGE QUALITY; IMMUNOFLUORESCENCE MICROSCOPY; MOUSE; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; SQUAMOUS CELL CARCINOMA; TUMOR MODEL;

ANIMALS; ANOXIA; CARCINOMA, SQUAMOUS CELL; CELL COUNT; CELL HYPOXIA; DISEASE MODELS, ANIMAL; FEMALE; MICE; MICE, INBRED C3H; NITROIMIDAZOLES; OXYGEN; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; RANDOM ALLOCATION; SENSITIVITY AND SPECIFICITY; TISSUE DISTRIBUTION;

EID: 69949180403     PISSN: 01678140     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.radonc.2009.08.026     Document Type: Article

References (35)

1. Vaupel P. Tumor microenvironmental physiology and its implications for radiation oncology. Semin Radiat Oncol 14 (2004) 198-206
2. Nordsmark M., Overgaard M., and Overgaard J. Pretreatment oxygenation predicts radiation response in advanced squamous cell carcinoma of the head and neck. Radiother Oncol 41 (1996) 31-39
3. Nordsmark M., Alsner J., Keller J., Nielsen O.S., Jensen O.M., Horsman M.R., et al. Hypoxia in human soft tissue sarcomas: adverse impact on survival and no association with p53 mutations. Br J Cancer 84 (2001) 1070-1075
4. Nordsmark M., Bentzen S.M., Rudat V., Brizel D., Lartigau E., Stadler P., et al. Prognostic value of tumor oxygenation in 397 head and neck tumors after primary radiation therapy. An international multi-center study. Radiother Oncol 77 (2005) 18-24
5. Thorwarth D., Eschmann S.M., Paulsen F., and Alber M. Hypoxia dose painting by numbers: a planning study. Int J Radiat Oncol Biol Phys 68 (2007) 291-300
6. Overgaard J., and Horsman M.R. Modification of hypoxia-induced radioresistance in tumors by the use of oxygen and sensitizers. Semin Radiat Oncol 6 (1996) 10-21
7. Kaanders J.H., Pop L.A., Marres H.A., Bruaset I., van den Hoogen F.J., Merkx M.A., et al. ARCON: experience in 215 patients with advanced head-and-neck cancer. Int J Radiat Oncol Biol Phys 52 (2002) 769-778
8. Sorensen B.S., Horsman M.R., Vorum H., Honore B., Overgaard J., and Alsner J. Proteins upregulated by mild and severe hypoxia in squamous cell carcinomas in vitro identified by proteomics. Radiother Oncol 92 (2009) 443-449
9. Quennet V., Yaromina A., Zips D., Rosner A., Walenta S., Baumann M., et al. Tumor lactate content predicts for response to fractionated irradiation of human squamous cell carcinomas in nude mice. Radiother Oncol 81 (2006) 130-135
10. Nordsmark M., Eriksen J.G., Gebski V., Alsner J., Horsman M.R., and Overgaard J. Differential risk assessments from five hypoxia specific assays: the basis for biologically adapted individualized radiotherapy in advanced head and neck cancer patients. Radiother Oncol 83 (2007) 389-397
11. Eriksen J.G., and Overgaard J. Lack of prognostic and predictive value of CA IX in radiotherapy of squamous cell carcinoma of the head and neck with known modifiable hypoxia: an evaluation of the DAHANCA 5 study. Radiother Oncol 83 (2007) 383-388
12. Sorensen B.S., Hao J., Overgaard J., Vorum H., Honore B., Alsner J., et al. Influence of oxygen concentration and pH on expression of hypoxia induced genes. Radiother Oncol 76 (2005) 187-193
13. Sorensen B.S., Alsner J., Overgaard J., and Horsman M.R. Hypoxia induced expression of endogenous markers in vitro is highly influenced by pH. Radiother Oncol 83 (2007) 362-366
14. Ljungkvist A.S., Bussink J., Kaanders J.H., and van der Kogel A.J. Dynamics of tumor hypoxia measured with bioreductive hypoxic cell markers. Radiat Res 167 (2007) 127-145
15. Sun X., Li X.F., Russell J., Xing L., Urano M., Li G.C., et al. Changes in tumor hypoxia induced by mild temperature hyperthermia as assessed by dual-tracer immunohistochemistry. Radiother Oncol 88 (2008) 269-276
16. Rajendran J.G., Hendrickson K.R., Spence A.M., Muzi M., Krohn K.A., and Mankoff D.A. Hypoxia imaging-directed radiation treatment planning. Eur J Nucl Med Mol Imaging 33 (2006) 44-53
17. Busk M., Horsman M.R., and Overgaard J. Resolution in PET hypoxia imaging: voxel size matters. Acta Oncol 47 (2008) 1201-1210
18. 18F]-MISO in rodent tumor models. Radiother Oncol 89 (2008) 353-360
19. 2-polarography, and fluorescence microscopy. Int J Radiat Oncol Biol Phys 70 (2008) 1202-1212
20. 18)F]FMISO autoradiography and pimonidazole immunohistochemistry in human head and neck carcinoma xenografts. Eur J Nucl Med Mol Imaging 35 (2008) 1803-1811
21. Knoess C., Siegel S., Smith A., Newport D., Richerzhagen N., Winkeler A., et al. Performance evaluation of the microPET R4 PET scanner for rodents. Eur J Nucl Med Mol Imaging 30 (2003) 737-747
22. 18F-fluoroazomycin arabinoside. J Nucl Med 46 (2005) 106-113
23. 18F]FAZA PET in head and neck cancer patients: a pilot study. Eur J Nucl Med Mol Imaging 34 (2007) 1566-1575
24. 18F]FAZA - first small animal PET results. J Pharm Pharm Sci 10 (2007) 203-211
25. 124)I-IAZG PET in the same study cohort. Eur J Nucl Med Mol Imaging 35 (2008) 39-46
26. Busk M., Horsman M.R., Jakobsen S., Bussink J., van der K.A., and Overgaard J. Cellular uptake of PET tracers of glucose metabolism and hypoxia and their linkage. Eur J Nucl Med Mol Imaging 35 (2008) 2294-2303
27. Wijffels K.I., Kaanders J.H., Rijken P.F., Bussink J., van den Hoogen F.J., Marres H.A., et al. Vascular architecture and hypoxic profiles in human head and neck squamous cell carcinomas. Br J Cancer 83 (2000) 674-683
28. 18F-fluoromisonidazole PET correlates with radiation treatment outcome in head-and-neck cancer. BMC Cancer 5 (2005) 152-160
29. 18)F-misonidazole and PET: changes of kinetics during radiotherapy of head-and-neck cancer. Radiother Oncol 83 (2007) 406-410
30. Airley R.E., Loncaster J., Raleigh J.A., Harris A.L., Davidson S.E., Hunter R.D., et al. GLUT-1 and CAIX as intrinsic markers of hypoxia in carcinoma of the cervix: relationship to pimonidazole binding. Int J Cancer 104 (2003) 85-91
31. Busk M., Horsman M.R., Kristjansen P.E., van der Kogel A.J., Bussink J., and Overgaard J. Aerobic glycolysis in cancers: implications for the usability of oxygen-responsive genes and fluorodeoxyglucose-PET as markers of tissue hypoxia. Int J Cancer 122 (2008) 2726-2734
32. Jonathan R.A., Wijffels K.I., Peeters W., de Wilde P.C., Marres H.A., Merkx M.A., et al. The prognostic value of endogenous hypoxia-related markers for head and neck squamous cell carcinomas treated with ARCON. Radiother Oncol 79 (2006) 288-297
33. Said H.M., Hagemann C., Staab A., Stojic J., Kuhnel S., Vince G.H., et al. Expression patterns of the hypoxia-related genes osteopontin, CA9, erythropoietin, VEGF and HIF-1alpha in human glioma in vitro and in vivo. Radiother Oncol 83 (2007) 398-405
34. Olive P.L., quino-Parsons C., MacPhail S.H., Liao S.Y., Raleigh J.A., Lerman M.I., et al. Carbonic anhydrase 9 as an endogenous marker for hypoxic cells in cervical cancer. Cancer Res 61 (2001) 8924-8929
35. Boado R.J., and Pardridge W.M. Glucose deprivation and hypoxia increase the expression of the GLUT1 glucose transporter via a specific mRNA cis-acting regulatory element. J Neurochem 80 (2002) 552-554